Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2025-01-17 AGM Information
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Please find enclosed notice of an Extra-Ordinary General Meeting scheduled to be held on Monday, February 10, 2025 at 2.00 p.m. (IST) through VC/ OAVM.
AGM Information Classification · 95% confidence The document is a detailed notice of an Extra-Ordinary General Meeting (EGM) scheduled for February 10, 2025, including the agenda for the meeting, voting procedures, and regulatory compliance references. It is not a report of financial results, audit, or management discussion, but rather a formal announcement and invitation to shareholders to participate in the EGM. The content includes the agenda item for approval of a business transfer agreement, procedural notes, and instructions for e-voting, which are typical for meeting notices. There is no financial data or analysis presented, nor is it a transcript or presentation. Therefore, this document fits the category of a meeting notice, which aligns with the category of AGM Information (AGM-R) or more broadly meeting notices. However, since this is an Extra-Ordinary General Meeting notice and not an Annual General Meeting, the closest fitting category from the provided list is AGM Information (AGM-R), as it covers presentations and materials shared during general meetings including EGMs. The document is substantive and not a brief announcement, so it is not RPA or RNS. Hence, the classification is AGM-R with high confidence.
2025-01-17 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice of an Extra-Ordinary General Meeting (EGM) scheduled for February 10, 2025, including the agenda for the meeting, voting procedures, and regulatory compliance references. It is not a report of financial results or management discussion but a formal meeting notice sent to shareholders. The content includes the date, time, venue (virtual), agenda items, and procedural instructions for shareholders to participate and vote. This matches the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. It is not an announcement of voting results (DVA), nor a report of the meeting itself. The document length and detail confirm it is not a brief announcement or a regulatory filing. Therefore, the correct classification is PSI with high confidence.
2025-01-17 English
Please find attached outcome of Board Meeting.
Capital/Financing Update Classification · 95% confidence The document is an official communication from Morepen Laboratories Limited to stock exchanges (NSE and BSE) regarding the outcome of a Board of Directors meeting held on January 14, 2025. The subject is the approval of the hiving off (slump sale) of the Medical Devices Business to a newly incorporated subsidiary, Morepen Medtech Limited. The document includes detailed disclosures as required under SEBI Listing Regulations, including financial details of the business segment, regulatory compliance, related party transaction status, and expected completion timeline. This is a corporate announcement about a significant transaction and restructuring approved by the Board, not a full financial report or earnings release. It is not a proxy, voting result, or remuneration report. It is a regulatory announcement about a corporate action (slump sale) approved by the Board and disclosed to the stock exchanges as per regulatory requirements. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to a significant change in the company's business structure and capital allocation through a slump sale transaction.
2025-01-14 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is an official communication from Morepen Laboratories Limited to stock exchanges (NSE and BSE) regarding the outcome of a Board of Directors meeting held on January 14, 2025. The key subject is the approval of a 'slump sale' of the Medical Devices Business to a newly incorporated subsidiary, Morepen Medtech Limited. The document includes detailed disclosures as required under SEBI Listing Regulations, including financial details of the business segment, regulatory compliance, related party transaction status, and expected completion timeline. The document is a formal announcement of a corporate action approved by the Board, not a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion and analysis but rather informs the market about a significant corporate restructuring transaction. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as business divestitures or asset sales. The document length (9923 characters) and content confirm it is a detailed announcement, not a brief notice or a report publication announcement.
2025-01-14 English
Outcome of Board Meeting
Regulatory Filings Classification · 95% confidence The document is an official communication from Morepen Laboratories Limited to stock exchanges (NSE and BSE) regarding the outcome of a Board of Directors meeting held on January 14, 2025. The key subject is the approval of a 'slump sale' of the Medical Devices Business to a newly incorporated subsidiary, Morepen Medtech Limited. The document includes detailed disclosures as required under SEBI Listing Regulations, including financial details of the business segment, regulatory compliance, related party transaction status, and expected timelines for completion. This is a corporate announcement about a significant transaction approved by the Board, not a full financial report or earnings release. It is not a proxy, voting result, or management discussion. The document is regulatory in nature, providing material information about a corporate restructuring transaction to the stock exchanges as per regulatory requirements. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance disclosure.
2025-01-14 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the incorporation of a new subsidiary company, Morepen Medtech Limited. It includes detailed disclosures about the subsidiary such as shareholding, business purpose, and incorporation details. The document is an announcement of a corporate event related to capital structure and subsidiary formation, not a full financial report or earnings release. It fits best under Capital/Financing Update (CAP) as it informs about a capital-related corporate action (subsidiary incorporation and shareholding). The document length is about 5935 characters, which is sufficient for a detailed announcement but not a full report like an annual or interim report.
2025-01-08 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.